山東威達(002026.SZ):子公司與哈工大機器人(山東)智能裝備研究院終止戰略合作協議
格隆匯4月10日丨山東威達(002026.SZ)公佈,此前披露,公司全資子公司濟南第一機牀有限公司於2019年4月10日與哈工大機器人(山東)智能裝備研究院簽署《戰略合作協議》,雙方決定結成戰略合作伙伴關係,依託濟南第一機牀有限公司在金屬切削中高檔數控機牀行業的研發製造優勢和哈工大機器人(山東)智能裝備研究院在智能裝備研發製造的技術積累,開展全面戰略合作。
自《戰略合作協議》簽署後,雙方就後續合作進行了積極的溝通,努力推進相關合作事項,但未有實質性的進展。現根據實際情況,經雙方友好協商,一致同意終止該《戰略合作協議》,並於2022年4月9日簽署了《戰略合作協議之終止協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.